Related Experiment Video

Updated: Jun 28, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer

Lyndee L Scurr1, Alexander D Guminski, Yoke-Eng Chiew

  • 1Westmead Institute for Cancer Research, University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 5, 2008
PubMed
Abstract

Insights

Researchers identified ANKRD1 as a key gene influencing platinum sensitivity in ovarian cancer. Decreasing ANKRD1 expression may enhance chemotherapy effectiveness, offering a new strategy for treating this disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Platinum-based chemotherapy is standard for ovarian cancer but predicting sensitivity and overcoming resistance remains challenging.
  • Identifying novel therapeutic targets is crucial for improving treatment outcomes in ovarian cancer.

Purpose of the Study:

  • To identify genes associated with cisplatin sensitivity in ovarian cancer using a novel approach.
  • To explore ANKRD1 as a potential therapeutic target for sensitizing ovarian tumors to platinum-based chemotherapy.

Main Methods:

  • Differential display PCR was used to identify differentially expressed genes in cisplatin-sensitive cell lines.
  • Gene transfection and siRNA were employed to validate the role of ANKRD1 in cisplatin sensitivity.
  • Expression levels of ANKRD1 were correlated with patient survival in a cohort of ovarian adenocarcinoma patients.

Main Results:

  • ANKRD1 (ankyrin repeat domain 1) was identified as the most highly differentially expressed gene.
  • ANKRD1 mRNA levels correlated with platinum sensitivity; siRNA-mediated knockdown increased cisplatin sensitivity over twofold.
  • ANKRD1 was expressed in 87% of ovarian adenocarcinomas, with higher levels associated with poorer patient survival.

Conclusions:

  • ANKRD1 is a novel gene associated with ovarian cancer treatment outcome and platinum response.
  • Targeting ANKRD1 expression or function presents a potential strategy to sensitize ovarian tumors to platinum-based chemotherapy.

More Related Videos

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Conservation of Protein Domains Over Different Proteins02:26

Conservation of Protein Domains Over Different Proteins

Protein domains are small structurally independent units that are part of a single amino acid chain.  Although these domains are often structurally independent, they may rely on synergistic effects to perform their functions as part of a larger protein. Protein domains may be conserved within the same organism, as well as across different organisms.
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to form...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...